Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.
Uwe PleyerSalem Al-MutairiConor C MurphyRola HamamShereen HammadOrsolya NagyZsuzsanna SzepessyYan Guex-CrosierKarina JulianZohar Habot-WilnerSofia AndroudiPublished in: The British journal of ophthalmology (2022)
These results demonstrated adalimumab effectiveness in improving quality of life while reducing economic burden of active NIIPPU.